Disc Medicine Inc. (IRON)
NASDAQ: IRONHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 7, 4:00 PM ET · Delayed 15 min
IRON stock chart
Technical analysisKey statistics
All statistics- Market cap
- $2.35B
- EPS (TTM)
- -$6.58
- Dividend yield
- None
- 52-week range
- 40.00 – 99.50
- Day range
- 60.02 – 62.59
- Volume / Avg
- 535.01K / 462.35K
- Beta
- —
- Shares outstanding
- 38.39M
- Next earnings
- Nov 5, 2026
52-week range
IRON stock today
Disc Medicine (IRON) closed at $61.18 on Oct 7, down 0.76% (-$0.47), versus the S&P 500's 0.22% decline. At this level, IRON sits in the middle of its 52-week range of $40.00 to $99.50: 38.5% below the high, set on Dec 8, 2025 and 52.9% above the low. IRON is down 23.0% year to date, underperforming the S&P 500 (+14.0%). Over the past 12 months, the stock has lost 9.9%.
Disc Medicine has posted a net loss over the last twelve months (EPS of -$6.58), so its P/E ratio is not meaningful. Disc Medicine's next earnings report is expected on Nov 5, 2026.
Summary generated from market data by MetaCap's automated system. Methodology
About Disc Medicine
Company profileDisc Medicine, Inc., together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for the treatment of erythropoietic porphyrias, including erythropoietic protoporphyria, X-linked protoporphyria, and diamond-blackfan anemia; DISC-0974 for the treatment of anemia of myelofibrosis, and anemia of chronic kidney disease; and DISC-3405 for the treatment of polycythemia vera, and other hematologic disorders.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Dr. John D. Quisel Esq., J.D., Ph.D.
- Headquarters
- Watertown, MA
- Employees
- 165
- Website
- discmedicine.com
Analyst forecast
ForecastConsensus (13 analysts)
strong_buy
Avg. price target
$103.17+68.63%
- Strong buy 1
- Buy 12
- Hold 0
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Next report
- Nov 5, 2026
- EPS estimate
- $-1.65
Disc Medicine peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| NRIXNurix Therapeutics Inc. | 22.73 | +0.58% | $2.36B | vs IRON |
| LQDALiquidia Corporation | 26.68 | +2.97% | $2.39B | vs IRON |
| BHCBausch Health Companies Inc. | 6.15 | +2.16% | $2.30B | vs IRON |
| HRMYHarmony Biosciences Holdings Inc. | 39.34 | -0.05% | $2.29B | vs IRON |
| SLSSELLAS Life Sciences Group Inc. | 11.31 | -0.26% | $2.28B | vs IRON |
| PBHPrestige Consumer Healthcare Inc. | 47.57 | +2.43% | $2.25B | vs IRON |
| IMNMImmunome Inc. | 19.10 | -1.11% | $2.25B | vs IRON |
| HCMHUTCHMED (China) Limited ADR | 14.28 | -2.19% | $2.48B | vs IRON |
Indexes, lists and sector
Disc Medicine stock FAQ
What is Disc Medicine's stock price today?
IRON last traded at $61.18 as of Oct 7, 4:00 PM EDT, down 0.76% on the day. Prices are delayed at least 15 minutes.
Does Disc Medicine pay a dividend?
No. Disc Medicine does not currently pay a regular cash dividend.
When is Disc Medicine's next earnings date?
Disc Medicine is expected to report earnings on Thursday, November 5, 2026. Analysts expect EPS of $-1.65.
Who is Disc Medicine's CEO?
Dr. John D. Quisel Esq., J.D., Ph.D. is the chief executive officer of Disc Medicine Inc., which has about 165 employees.
Has IRON ever split its stock?
Yes. The most recent IRON stock split was a 1-for-30 split on Dec 30, 2022.
What is the IRON 52-week high?
The 52-week high for IRON is $99.50 and the 52-week low is $40.00. The stock is currently 38.5% below its high.